Federated Investors Inc. PA raised its position in Epizyme, Inc. (NASDAQ:EPZM) by 477.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 89,505 shares of the biopharmaceutical company’s stock after acquiring an additional 74,009 shares during the quarter. Federated Investors Inc. PA owned approximately 0.15% of Epizyme worth $1,352,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of EPZM. Palo Alto Investors LLC lifted its stake in Epizyme by 57.8% in the first quarter. Palo Alto Investors LLC now owns 4,791,051 shares of the biopharmaceutical company’s stock worth $82,167,000 after acquiring an additional 1,755,255 shares during the last quarter. Oracle Investment Management Inc. purchased a new position in Epizyme in the first quarter worth approximately $8,866,000. Vanguard Group Inc. lifted its stake in Epizyme by 4.5% in the first quarter. Vanguard Group Inc. now owns 3,218,862 shares of the biopharmaceutical company’s stock worth $55,202,000 after acquiring an additional 139,066 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Epizyme in the first quarter worth approximately $1,975,000. Finally, Foresite Capital Management III LLC lifted its stake in Epizyme by 12.7% in the first quarter. Foresite Capital Management III LLC now owns 681,922 shares of the biopharmaceutical company’s stock worth $11,695,000 after acquiring an additional 76,683 shares during the last quarter. Institutional investors own 83.74% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Federated Investors Inc. PA Purchases 74,009 Shares of Epizyme, Inc. (EPZM)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/14/federated-investors-inc-pa-purchases-74009-shares-of-epizyme-inc-epzm.html.

In other Epizyme news, CFO Andrew E. Singer sold 3,024 shares of the stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $15.50, for a total value of $46,872.00. Following the completion of the sale, the chief financial officer now owns 40,529 shares of the company’s stock, valued at $628,199.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $14.87, for a total value of $223,050.00. Following the transaction, the insider now owns 22,228 shares of the company’s stock, valued at $330,530.36. The disclosure for this sale can be found here. Insiders sold 48,024 shares of company stock valued at $706,722 in the last ninety days. 25.20% of the stock is owned by corporate insiders.

Shares of Epizyme, Inc. (NASDAQ:EPZM) opened at 15.95 on Thursday. The stock’s 50 day moving average is $14.77 and its 200 day moving average is $15.13. Epizyme, Inc. has a 12 month low of $8.00 and a 12 month high of $18.80. The stock’s market cap is $932.53 million.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.08. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 63.10%. The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.95 million. During the same quarter last year, the company earned ($0.49) earnings per share. Epizyme’s revenue for the quarter was up 2027.7% on a year-over-year basis. Analysts predict that Epizyme, Inc. will post ($2.39) earnings per share for the current fiscal year.

A number of brokerages recently issued reports on EPZM. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research note on Monday, August 7th. Leerink Swann reiterated an “outperform” rating and issued a $28.00 price target (down previously from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Royal Bank Of Canada set a $20.00 price target on shares of Epizyme and gave the stock a “buy” rating in a research note on Saturday, August 5th. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research note on Wednesday, June 7th. Finally, BidaskClub upgraded shares of Epizyme from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.38.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.